Bristol-Myers: FDA blocks hepatitis C drug for now
U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir.
Nov 26, 2014
U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir.
Nov 26, 2014
A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates ...
Nov 26, 2014
Work supported by the Stand Up To Cancer (SU2C) - Cancer Research Institute (CRI) - Immunology Translational Research Dream Team, launched in 2012 to focus on how the patient's own immune system can be harnessed to treat ...
Nov 26, 2014